Literature DB >> 2416687

Immunogenicity and antigenicity of synthetic Escherichia coli lipid A.

L Brade, E T Rietschel, S Kusumoto, T Shiba, H Brade.   

Abstract

The immunogenicity and antigenicity of synthetic Escherichia coli lipid A (compound 506) and its 1- and 4'-monophosphorylated derivatives (compounds 505 and 504, respectively) and nonphosphorylated derivative (compound 503) were compared with those of bis- and 4'-monophosphorylated natural free lipid A from E. coli. The synthetic compounds under study were either coated onto sheep erythrocytes (except for the water-insoluble preparation 503) or incorporated into liposomes and used for the immunization of rabbits. Both types of immunogens (the latter representing fully synthetic immunogens) resulted in high-titered polyclonal antisera which were characterized before or after absorption in a passive hemolysis assay as well as in a passive hemolysis inhibition assay with the synthetic compounds as test antigens. All antisera were found to react with their corresponding homologous antigens coated onto sheep erythrocytes, with titers of up to 2,048, and were comparable to those antisera obtained after immunization with natural lipid A exposed on the bacterial surface after acid hydrolysis. Antisera against bisphosphorylated compound 506 were highly specific for the homologous antigens, showing no interaction with compounds 504 and 505 in the passive hemolysis test. The same held true for the absorption experiments in which glutaraldehyde-fixed sheep erythrocytes were sensitized with the respective antigens. Antisera against monophosphorylated compounds 504 and 505 exhibited, besides their expected homologous reactivity, complete cross-reactivity with compound 506, but they did not cross-react with each other. Thus, anti-504 and anti-505 antibodies recognized distinct antigenic determinants, being related to the ester linked 4'-phosphate or the glycosidically linked 1-phosphate, respectively. Both antigenic determinants were also expressed by bisphosphorylated compound 506 used as an antigen; however, upon immunization, only antibodies against compound 506 were elicited.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2416687      PMCID: PMC261072          DOI: 10.1128/iai.51.1.110-114.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  8 in total

1.  In vitro antigenic reactivity of synthetic lipid A analogues as determined by monoclonal and conventional antibodies.

Authors:  N Kasai; S Arata; J Mashimo; K Okuda; Y Aihara; S Kotani; H Takada; T Shiba; S Kusumoto
Journal:  Biochem Biophys Res Commun       Date:  1985-04-30       Impact factor: 3.575

2.  Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities.

Authors:  C Galanos; O Lüderitz; E T Rietschel; O Westphal; H Brade; L Brade; M Freudenberg; U Schade; M Imoto; H Yoshimura
Journal:  Eur J Biochem       Date:  1985-04-01

3.  Production of antibodies against phosphocholine, phosphatidylcholine, sphingomyelin, and lipid A by injection of liposomes containing lipid A.

Authors:  B G Schuster; M Neidig; B M Alving; C R Alving
Journal:  J Immunol       Date:  1979-03       Impact factor: 5.422

4.  Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides.

Authors:  C Galanos; O Lüderitz; O Westphal
Journal:  Eur J Biochem       Date:  1971-12-22

5.  Characterization of two different antibody specificities recognizing distinct antigenic determinants in free lipid A of Escherichia coli.

Authors:  L Brade; H Brade
Journal:  Infect Immun       Date:  1985-06       Impact factor: 3.441

6.  Lipid A from endotoxin: antigenic activities of purified fractions in liposomes.

Authors:  B Banerji; C R Alving
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

7.  Concepts of the chemical structure of lipid A.

Authors:  E T Rietschel; H W Wollenweber; R Russa; H Brade; U Zähringer
Journal:  Rev Infect Dis       Date:  1984 Jul-Aug

8.  Immunogenic properties of lipid A.

Authors:  C Galanos; M A Freudenberg; F Jay; D Nerkar; K Veleva; H Brade; W Strittmatter
Journal:  Rev Infect Dis       Date:  1984 Jul-Aug
  8 in total
  8 in total

1.  Characterization of the epitope specificity of murine monoclonal antibodies directed against lipid A.

Authors:  H M Kuhn; L Brade; B J Appelmelk; S Kusumoto; E T Rietschel; H Brade
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

2.  [Lipopolysaccharides, endotoxins and O-antigens of gram-negative bacteria: chemical structure, biologic effect and serologic properties].

Authors:  E T Rietschel; H Brade
Journal:  Infection       Date:  1987 Mar-Apr       Impact factor: 3.553

3.  [Lipopolysaccharides, endotoxins and O-antigens of gram-negative bacteria: chemical structure, biologic effect and serologic properties].

Authors:  E T Rietschel; H Brade
Journal:  Infection       Date:  1987       Impact factor: 3.553

4.  A nonsubstituted primary hydroxyl group in position 6' of free lipid A is required for binding of lipid A monoclonal antibodies.

Authors:  L Brade; R Engel; W J Christ; E T Rietschel
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

5.  Cross-reactivity of monoclonal antibodies and sera directed against lipid A and lipopolysaccharides.

Authors:  H M Kuhn
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

6.  The immunogenicity and antigenicity of lipid A are influenced by its physicochemical state and environment.

Authors:  L Brade; K Brandenburg; H M Kuhn; S Kusumoto; I Macher; E T Rietschel; H Brade
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

7.  Immune response of rabbits to lipid A: influence of immunogen preparation and distribution of various lipid A specificities.

Authors:  H M Kuhn
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

8.  Use of synthetic antigens to determine the epitope specificities of monoclonal antibodies against the 3-deoxy-D-manno-octulosonate region of bacterial lipopolysaccharide.

Authors:  L Brade; P Kosma; B J Appelmelk; H Paulsen; H Brade
Journal:  Infect Immun       Date:  1987-02       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.